Neuroendocrine Tumours, Surgical — Grade the Biology, Spare Parenchyma Where Safe, and Resect Liver Disease by Extent

The neuroendocrine tumour wants four verdicts before the knife — what grade is it, is the small pancreatic lesion safer watched or resected, which parenchyma-sparing operation earns cure for functional disease, and how much liver can be taken at once — because grade-3 well-differentiated disease sits prognostically between low-grade tumour and carcinoma, surgery halves pancreatic mortality against nonoperative care yet matches it below one centimetre, enucleation trades fistula for preserved function, and simultaneous pancreas-plus-liver surgery costs more than liver-alone surgery. Grade by morphology, judge small lesions by size plus location and proliferation, spare parenchyma for insulinoma where feasible, open every gastrinoma duodenum, earn the appendiceal colectomy with invasion arithmetic, resect liver by anatomic extent, resuscitate crisis with vasopressors first, and survey the heart by serotonin — with every number taken from the papers named beside it.^{[33][1][10][8][25]}

A 34-year-old woman with a 1.4 cm distal nonfunctioning pancreatic lesion and low proliferation; a 41-year-old man with Whipple triad and a localised insulinoma; and a 52-year-old man with Zollinger-Ellison syndrome, a duodenal primary and liver-free imaging. One needs the surveillance-versus-resection verdict with node-risk scoring, one needs localisation then parenchyma-sparing excision, and one needs duodenotomy with nodal clearance for cure. The examiner will watch you separate grade-3 tumour from carcinoma, defend enucleation with fistula-versus-function arithmetic, quote duodenotomy cure gains, set the appendiceal colectomy threshold, choose liver extent, run crisis on vasopressors, and place somatostatin and radioligand therapy — with every number taken from the papers named beside it.^[13][16][17]

Surgery is the curative anchor across resectable pancreatic disease: pooling 77 studies with 62,654 patients, operative management carries a mortality hazard of 0.30 with 1-, 3-, 5- and 10-year survival at 94, 85, 77 and 64% against 78, 57, 46 and 34% without surgery — better across functional, nonfunctional, low-grade and metastatic presentations — while disease below one centimetre shows comparable survival either way, so the operation is default above that line and selective below it.^[10] The strategic arc fits one sentence: grade the biology, judge small pancreatic lesions by size with location and proliferation, spare parenchyma for benign functional disease, open the duodenum for gastrinoma with nodes, earn appendiceal colectomy by invasion, resect liver anatomically where possible, resuscitate crisis with vasopressors, survey the heart, and place systemic adjuncts after surgery.^{[33][13][8][17][21][26][28][5]}

Grade the tumour, then plan the operation

High-grade disease is two entities, not one: the current WHO classification divides well-differentiated grade-3 tumours from poorly-differentiated carcinomas on morphology despite shared proliferation indices — a diagnostic challenge — with grade-3 tumours carrying lower proliferation and mutational burden and distinct genetics, so the pathologist's immunohistochemistry panel matters to the surgeon's plan.^[33] Grade-3 well-differentiated tumours comprise about one-fifth of high-grade neoplasms with prognosis worse than grade 1-2 disease but better than carcinoma; localised disease goes to surgery with neo-adjuvant and adjuvant roles still dilemmas, oligometastatic disease weighs surgery with ablation, and advanced disease starts temozolomide/capecitabine or fluorouracil-based chemotherapy rather than platinum/etoposide.^[1] Foregut luminal disease increasingly meets the endoscope: gastric, duodenal and rectal tumours rise with imaging advances, and technique selection, R1 significance, pathology and surveillance remain the controversies — managed multidisciplinarily by tumour, patient and procedural risk.^[2] Midgut small-bowel primaries with their mesenteric and carcinoid-syndrome logic live in the companion small-bowel-tumours topic; this topic owns pancreas, duodenum, stomach, appendix and rectum plus the metastatic liver that unites them.

Judge the small pancreatic tumour: watch or resect

Small nonfunctioning pancreatic disease is the fellowship's favourite trap because both watching and operating carry recommendations. The systematic review screens 3,915 records down to five retrospective studies with 540 patients: measurable growth appears in up to half, about one in seven crosses to resection mostly for size increase, and no surveilled patient dies of disease at 28-45 months — surveillance is a defensible alternative, not neglect.^[11] The American cancer database sharpens the line with 2,004 localised well-differentiated nonfunctioning tumours: resection improves survival above one centimetre while age, comorbidity, stage, location and the resection itself stand as independent prognostics — so surveillance is potentially safe below one centimetre and larger tumours need intervention.^[12] Size alone misleads, which is why the 2.5 cm reappraisal matters: across 5,172 pancreatic neoplasms the 2.5 cm line best predicts aggressiveness, and management must weigh grade, number and stage with size rather than size alone.^[14] Score nodes preoperatively instead of guessing: the 8-institution American study builds its 1-to-7 score from location and proliferation, categorising low, intermediate and high bands — so a distal low-proliferation lesion watches calmly while a proximal higher-proliferation one resects with nodes.^[13]

Spare parenchyma where oncology allows

Enucleation exists for small, preferably functional, peripheral disease — and its indications show it: among 1,034 resected pancreatic tumours only 13.8% undergo enucleation, chosen for small size around 1.5 cm and functional disease, mainly insulinoma at over half.^[8] The trade is explicit after matching: clinically significant fistula runs 24.5% after enucleation against 14.0% after formal resection, with recurrence-free survival comparable — higher leak, equivalent control.^[8] The multi-institutional selected series agrees that size above two centimetres need not forbid enucleation: patient characteristics match, node pickings run about one-third with higher harvests in larger tumours, R0 rates match, and characteristics differ only in diameter.^[7] Meta-analysis prices the whole exchange across seven comparative studies: enucleation is shorter with less blood loss, matched mortality, higher all-grade and B/C fistula, but markedly lower endocrine and exocrine insufficiency — parenchyma preserved at the price of leak.^[9]

Localise insulinoma, then excise it whole

Benign insulinoma is the commonest functioning pancreatic tumour yet rare at an estimated 0.4%, and organ-preserving resection is its treatment of choice.^[15] Expect delay — the Milan series of 98 operated patients reports a 10-month median from symptoms to diagnosis — then localise with everything: CT, MRI and endoscopic ultrasound in combination, with ultrasound the most sensitive and MRI and ultrasound each rescuing CT-negative tumours; parenchyma-sparing resections run in 41 of 98, formal resection reserved for vessel contact, duct proximity or suspected malignancy, and sparing is the rule whenever technically and oncologically feasible.^[16] Approach it minimally invasively when localised and feasible: the 71-patient bi-institutional enucleation comparison finds minimally invasive surgery shorter excluding conversions with equivalent late complications, 5.6% functional recurrence at 75 months median follow-up, and no disease recurrence after R1 resection — safe with at least similar short- and long-term outcomes to open surgery.^[15]

Cure gastrinoma with duodenotomy and nodes

Sporadic gastrinoma cures only by complete resection, and the duodenum hides the target: routine duodenotomy in 143 operated Zollinger-Ellison patients finds gastrinoma in 98% against 76% without it, with duodenal primaries at 62% against 18% — lifting immediate cure to 65% against 44% and long-term cure to 52% against 26% — so duodenotomy belongs in every curative operation for sporadic disease.^[17] The 10-year prospective protocol of 73 liver-free patients sets expectations honestly: imaging localises barely half, resection finds disease in 78%, operations carry no deaths with 11% morbidity, half the disease-free recur by five years, yet overall survival stays excellent against 20% five-year survival once metastatic at presentation — most are found and resected, about one-third cured long-term.^[18] Modern sporadic series confirm the excellent survival with frequent recurrence: 108 patients across 15 hospitals reach 173 months median survival with 94% at five years but only 63% disease-free, with size above two centimetres and grade independently predicting recurrence — and for duodenal primaries, duodenotomy with excision plus lymphadenectomy matches pancreaticoduodenectomy on survival, making the lesser operation valid absent oncologic superiority of the greater.^[19] MEN1 gastrinoma plays by harsher nodal rules: among 233 French-network patients only 28% reach gastrinoma surgery, nodes run positive in 71% of lymphadenectomies, operated non-metastatic survival at 15 years reads 82% against 70% unoperated without significance — with gastrin normalising best when duodenum and pancreatic head go together, favouring pancreaticoduodenectomy in young fit patients and resection alongside large pancreatic tumours.^[20] MEN1 nonfunctioning pancreatic tumours frame the wider dilemma: 30-80% of MEN1 patients develop them with metastatic sequelae driving early mortality, resection standard above two centimetres, and management below that line controversial without behaviour-predicting biomarkers.^[32]

Settle the appendix: size, invasion and the colectomy verdict

Appendiceal disease is usually an appendectomy surprise, and completion colectomy must be earned. The French national study of 403 nonmetastatic tumours sends one-quarter to completion with about one-quarter of those node-positive; size with a best cut near two centimetres plus lymphovascular, perineural and pT features associate with nodes — yet among 44 completions for 1-2 cm tumours, 18% carry nodes with no predictor found in that band.^[21] The American population study of 576 resected appendiceal carcinoids identifies size and histology as nodal predictors using its 1988-2005 registry cohort — but size-stratified survival shows no colectomy advantage over appendectomy alone.^[22] The high-risk challenge sharpens the scepticism: 34 patients with 22 carrying at least one high-risk feature, only three completions without residual disease, all but one accidental death alive and disease-free at a 117-month mean with no disease-free split by risk status — routine completion may not improve outcomes, pending larger multicentre proof.^[23] The decision model prices the middle band: for 10-20 mm well-differentiated disease, 10-year survival runs 98.2% watched against 98.9% resected, with surveillance superior on quality-adjusted expectancy and cost-effective near four thousand dollars per QALY — safe and economical to watch the centimetre-plus appendix tumour.^[24]

Resect liver disease by extent and timing

Between two-fifths and four-fifths of pancreatic tumours present with liver metastases, and debulking improves long-term survival — but simultaneity has a price. Among 1,917 liver resections with 494 simultaneous pancreas-plus-liver procedures, simultaneous surgery matches isolated pancreatic morbidity yet exceeds isolated liver resection with more transfusions and infections — comparable to the pancreas alone, costlier than the liver alone — with obesity independently predicting simultaneous morbidity.^[25] Extent matters once committed: the 258-patient 8-institution curative-intent cohort, nearly half pancreas and one-quarter small-bowel primaries, finds anatomic resection outliving non-anatomic on overall and recurrence-free survival, with non-anatomic independently raising recurrence — formal hepatectomy over wedge where feasible.^[26] Thresholds can widen without surrendering survival: the 52-patient expanded-criteria series accepting 70% debulking with extrahepatic disease and positive margins allowed reports 72-month median liver progression-free survival with 90% five-year disease-specific survival, all deaths from liver failure.^[27]

Tame crisis with vasopressors and survey the heart

Carcinoid crisis is sudden profound hypotension on the table, and doctrine has flipped: comparing 150 octreotide-first against 195 vasopressor-first operations, crisis strikes 30% against 25% with median six against three minutes — over one-quarter of octreotide crises dragging beyond ten minutes, 93% still needing vasopressors, three operations aborted — against no prolonged crises and no aborts with pressors first. Vasopressors are first-line; guidelines should change.^[28] Prophylaxis doctrine falls with it: the 195-operation prospective series without any perioperative octreotide documents crisis in one-quarter at three minutes mean — small-bowel primary, older age and carcinoid syndrome predicting it with more major complications — neither rate nor duration above octreotide-era studies, so routine prophylaxis may be stopped for inefficacy while better drugs are sought.^[29] The heart declares itself late and by serotonin: annual echo in 137 carcinoid-syndrome patients over a 54-month mean finds cardiac disease in 27% at baseline rising to 32% at five years, with 28% progression and 21% late occurrence — a 25% serotonin rise and peaks above 205 units predicting occurrence, demanding cardiology follow-up on recurrence.^[30] Risk thresholds quantify it prospectively: 252 patients with half-yearly echo over 29 months median, 44 developing or progressing — with serotonin and flushing surging at progression — so serotonin and daily flushing burden stratify who to watch closest.^[31]

Place systemic therapy around surgery

Somatostatin analogues control growth as well as symptoms. PROMID randomises treatment-naive metastatic midgut tumours to octreotide LAR or placebo: time to progression 14.3 against 6 months with two-thirds against one-third stable at six months, functioning and nonfunctioning alike, best with low liver load and resected primary — survival unconfirmed on few deaths.^[5] CLARINET extends the principle to enteropancreatic grade 1-2 disease below 10% proliferation: lanreotide against placebo gives median unreached against 18.0 months with 65.1% against 33.0% progression-free at two years, diarrhoea the commonest toxicity at 26% against 9%.^[6] Radioligand therapy crowns the sequence after somatostatin progression: the 229-patient NETTER-1 randomisation in progressive receptor-positive midgut disease reports markedly longer progression-free survival with higher response and under 10% significant myelosuppression.^[3] Final NETTER-1 follow-up at 76 months median tempers the survival claim honestly: 48.0 against 36.3 months without significance — an 11.7-month gap potentially clinically relevant — with 3% severe treatment-related events, 2% myelodysplasia with one treatment death, and no new late signals.^[4]

The cohorts behind the numbers run McNamara ENETS grade-3 position, Panzuto ENETS endoscopic position, Strosberg NETTER-1 with final survival, Rinke PROMID, Caplin CLARINET, Karam multi-institutional enucleation, Heidsma 1,034 resections with matching, Chua enucleation meta-analysis, Khajeh 77 studies with 62,654 patients, Partelli five-study surveillance review, Assi 2,004 NCDB patients, Lopez-Aguiar 309 small resections with risk score, Yang 5,172 SEER patients with 2.5 cm reappraisal, Belfiori 71 insulinomas, Andreasi 98 Milan insulinomas, Norton duodenotomy with 143 operations and 10-year 73-patient protocol, Robin 108 sporadic gastrinomas, Gaujoux 233 MEN1 gastrinomas, Rault-Petit 403 French appendiceal tumours, Groth 576 SEER appendiceal carcinoids, Canbak 34 high-risk appendiceal tumours, Ricci Markov appendiceal model, Kone 1,917 liver resections with 494 simultaneous, Sham 258 international liver resections, Graff-Baker 52 expanded debulkings, McCully 345 crisis operations, Wonn 195 no-octreotide operations, Baron 137 echo patients, Bhattacharyya 252 prospective echo patients, Challis MEN1 review, and Sun grade-3 pathology review — randomised where randomisable, nationwide and multicentre where rare, pooled where small.^{[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]}

Small pancreas, duodenal gastrin and the appendix close the traps: the sub-centimetre pancreatic lesion watches while the scored intermediate-high lesion resects with nodes; insulinoma localises thrice then shells minimally invasively where feasible; every sporadic gastrinoma gets duodenotomy with nodes since imaging misses duodenal primaries; the 1-2 cm appendix tumour without invasion watches at 98% ten-year survival while invaded or large disease earns colectomy; simultaneous pancreas-liver surgery is staged or selected in obesity; crisis runs on vasopressors with octreotide retired to second line; and the carcinoid heart gets echo before and after recurrence since serotonin writes the valves.^{[12][13][16][15][17][24][25][28][30]}

5-study review at 540 patients with 28-45 month follow-up; measurable growth 0-51%, 14.1% crossed to resection mostly for size increase, zero disease-related deaths on surveillance (PMID 27706803).^[20][11] Localise insulinoma exactly: Milan 98-patient series with 10-month median symptom-to-diagnosis delay; CT 84%, MRI 85%, EUS 100% sensitivity with MRI and EUS rescuing CT-negative tumours; parenchyma-sparing in 41 with formal resection for vessel, duct or malignancy concern (PMID 37915303).^[9][16] 10-year prospective 73-patient protocol with 78% found and resected, 11% morbidity, no deaths, 50% of disease-free recurring by 5 years against 20% 5-year survival when metastatic at presentation (PMID 1531004).^[18] 258-patient 8-institution curative-intent cohort at pancreas 45% and small bowel 25% primaries; anatomic resection outlives non-anatomic on OS and RFS with non-anatomic independently raising recurrence (PMID 29980977).^[25] 150 octreotide-first vs 195 vasopressor-first operations; crisis 30 vs 25% with median 6 vs 3 minutes and 27% prolonged beyond 10 minutes on octreotide; 93% of octreotide crises still needed vasopressors; vasopressor-first shortens crisis, anaesthesia and aborts (PMID 38227166).^[29][28] Survey the heart exactly: 137-patient echo series at 54-month mean follow-up; cardiac disease 27% baseline rising to 32% at 5 years with 28% progression and 21% late occurrence; 25% serotonin rise and peak above 205 mg/24 h predict occurrence (PMID 34816734).^[30][31] 85-patient interim analysis at 67 progressions; octreotide LAR extends time to progression 14.3 vs 6 months with 66.7 vs 37.2% stable at 6 months; best with low liver load and resected primary; survival unconfirmed (PMID 19704057).^[5] 229-patient midgut trial after somatostatin progression; lutetium therapy gives 20-month progression-free 65.2 vs 10.8% with 18 vs 3% response and under 10% significant myelosuppression (PMID 28076709).^[3]

References33ShowHide

1. [1]McNamara MG, et al. Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract. J Neuroendocrinol, 2025.PMID 40781987
2. [2]Panzuto F, et al. Controversies in NEN: An ENETS position statement on the endoscopic management of localised gastric, duodenal and rectal neuroendocrine neoplasms. J Neuroendocrinol, 2025.PMID 40524475
3. [3]Strosberg J, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med, 2017.PMID 28076709
4. [4]Strosberg JR, et al. (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol, 2021.PMID 34793718
5. [5]Rinke A, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol, 2009.PMID 19704057
6. [6]Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med, 2014.PMID 25014687
7. [7]Karam E, et al. Enucleation for Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors Larger than 2 Centimeters Is Associated with Equivalent Morbidity and Survival Compared to Smaller Tumors: A Multi-Institutional Study. Neuroendocrinology, 2024.PMID 39182485
8. [8]Heidsma CM, et al. Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. HPB (Oxford), 2021.PMID 32771338
9. [9]Chua TC, et al. Systematic Review and Meta-Analysis of Enucleation Versus Standardized Resection for Small Pancreatic Lesions. Ann Surg Oncol, 2016.PMID 26307231
10. [10]Khajeh E, et al. Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Ann Surg Oncol, 2025.PMID 40705264
11. [11]Partelli S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg, 2017.PMID 27706803
12. [12]Assi HA, et al. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist, 2020.PMID 32043766
13. [13]Lopez-Aguiar AG, et al. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019.PMID 31072670
14. [14]Yang Z, et al. Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study. Front Endocrinol (Lausanne), 2022.PMID 35923628
15. [15]Belfiori G, et al. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World J Surg, 2018.PMID 29691623
16. [16]Andreasi V, et al. Diagnostic work-up and surgical management of insulinoma: A retrospective analysis from a tertiary referral center. J Neuroendocrinol, 2023.PMID 37915303
17. [17]Norton JA, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg, 2004.PMID 15082965
18. [18]Norton JA, et al. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg, 1992.PMID 1531004
19. [19]Robin L, et al. Recurrence after surgical resection of nonmetastatic sporadic gastrinoma: Which prognostic factors and surgical procedure? Surgery, 2023.PMID 36781315
20. [20]Gaujoux S, et al. Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines). World J Surg, 2026.PMID 41862416
21. [21]Rault-Petit B, et al. Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE). Ann Surg, 2019.PMID 29557879
22. [22]Groth SS, et al. Appendiceal carcinoid tumors: Predictors of lymph node metastasis and the impact of right hemicolectomy on survival. J Surg Oncol, 2011.PMID 21031414
23. [23]Canbak T, et al. Evaluating the necessity of right hemicolectomy in high-risk appendiceal neuroendocrine tumors: a retrospective analysis. BMC Surg, 2025.PMID 40721749
24. [24]Ricci C, et al. Safety and cost-effectiveness of immediate right hemicolectomy versus active surveillance for well-differentiated appendiceal neuroendocrine tumors 1-2 cm in size: a Markov decision analysis. Endocrine, 2025.PMID 40640613
25. [25]Kone LB, et al. The morbidity of simultaneous pancreatic and liver resection for metastatic pancreatic neuroendocrine tumors. J Gastrointest Surg, 2025.PMID 40738420
26. [26]Sham JG, et al. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. J Gastrointest Surg, 2019.PMID 29980977
27. [27]Graff-Baker AN, et al. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery, 2014.PMID 25456912
28. [28]McCully BH, et al. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis. Ann Surg Oncol, 2024.PMID 38227166
29. [29]Wonn SM, et al. A prospective study of carcinoid crisis with no perioperative octreotide. Surgery, 2022.PMID 34226047
30. [30]Baron E, et al. Progression of Carcinoid Heart Disease in the Modern Management Era. J Am Heart Assoc, 2021.PMID 34816734
31. [31]Bhattacharyya S, et al. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol, 2011.PMID 21296329
32. [32]Challis BG, et al. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1? Clin Endocrinol (Oxf), 2019.PMID 31505044
33. [33]Sun BL, et al. Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms. Am J Clin Pathol, 2025.PMID 40037757